The PIM designation is the first step towards inclusion in the Early Access to Medicines Scheme (EAMS). Launched in April 2014, EAMS offers severely ill patients with life-threatening
The round was led by new investor Versant Ventures. Existing investors New Enterprise Associates, Novo A/S, NanoDimension and Flagship Pioneering also participated. Tarveda plans to use these financial
Milan Zdravkovic, Senior Vice President, Chief Medical Officer, and Head of Research & Development at Sobi, said: “Sobi has a long-term commitment to improve the lives for people
With this expanded capacity, Arven will support local healthcare needs by bringing biopharmaceuticals to the Turkish and surrounding markets faster, whilst also opening up European markets through the
The first-in-man clinical trial utilizes a single intravenous injection of AAV gene therapy for patients with MPS IIIA (Sanfilippo syndrome type A), a devastating lysosomal storage disease that
This study, which will enroll 40 healthy adults in U.S. sites, follows a successful Phase 1a single ascending dose clinical study completed in 2016. Preclinical studies have shown
The IND is now active and Audentes plans to initiate VALENS, the multicenter, multinational, open-label, ascending dose phase 1 / 2 clinical study of AT342. Preliminary data from
The assets acquired have been developed by Cantab Anti Infectives Ltd, a PBB group company. Ankit Mahadevia, M.D., Chief Executive Officer of Spero, said: “The acquisition of these
Scientists are searching for chemical drug candidates that can affect the key molecules and proteins that control cancer cells in several common childhood cancers. However, finding drug candidates
REVIVE-1 is a 600-patient double-blinded, global, multicenter trial, in patients with ABSSSI that compares the safety and efficacy of an 80mg intravenous dose of iclaprim with 15mg/kg intravenous
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.